While adjuvant topical mitomycin C (MMC) is well established in realms of bladder cancer, its use in upper tract urothelial tumours (UTUC) is still somewhat limited with only few series reported worldwide. The authors present their series of 27 patients (28 renal units) on the role of adjuvant MMC after complete endoscopic control of UTUC with a median follow-up of 19 months (7-92 months). Their recurrence free survival of 62% at 3 years represents a medium term favourable result, especially in low-grade tumours. It seems that although Nephroureterectomy still remains the gold standard for UTUC for now, endoscopic management in carefully selected patients will have a better recurrence free survival using protocol based adjuvant MMC instillation as shown by the authors in this series.
Journal of endourology. 2017 Aug 01 [Epub ahead of print]
Bhaskar K Somani
University Hospitals Southampton NHS Trust, Urology, Southampton, United Kingdom of Great Britain and Northern Ireland ; .